Combining Light Therapy and CPAP in Depression
Launched by HÔPITAL LE VINATIER · Jan 13, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effects of a combination of light therapy and a continuous positive airway pressure (CPAP) machine on patients suffering from major depression and obstructive sleep apnea (OSA). The goal is to see if using light therapy for two weeks alongside CPAP can help patients better adhere to their CPAP treatment, which is essential for improving their sleep quality and overall mental health.
To be eligible for the trial, participants must be adults aged 65 to 74 who have been diagnosed with a major depressive episode and have a specific score indicating the severity of their depression. They also need to have been diagnosed with obstructive sleep apnea, which requires CPAP treatment. However, certain individuals, such as those with specific eye conditions or unstable health issues, cannot participate. If you join the study, you can expect to receive light therapy and use a CPAP machine while being monitored for any changes in your depression and sleep patterns. Please note that this trial is not yet recruiting participants, but it aims to provide valuable insights into improving treatment for patients facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults consulting at the MICHEL JOUVET unit, CH Le Vinatier, Bron
- • Adults with a diagnosis of major depressive episode (DSM-V) and with a MADRS score ≥ 15
- • Adults with a diagnosis of OSAS on ventilatory polygraphy or polysomnography (AASM 2017 criteria) requiring CPAP.
- Exclusion Criteria:
- • Refusal to participate.
- • Pregnant and breast-feeding women
- • Under guardianship or curatorship.
- • Unstable psychiatric or physical pathology (e.g., hypomania, high suicidal risk) considered incompatible with the study by the investigators.
- • Other psychiatric, neurologic or somatic conditions
- • Contraindication to light therapy: retinopathy, retinitis pigmentosa, diabetic retinopathy, macular degeneration, glaucoma, recent eye surgery (less than 3 months).
- • patient wishing to choose a provider other than the protocol provider.
- • Patient wishing to choose a device other than SEFAM's S-BOX or a mask other than the nasal mask at the time of introduction.
- • Nasal obstruction.
- • Refusal to use actimetry, refusal to use light therapy, refusal to use CPAP.
About Hôpital Le Vinatier
Hôpital Le Vinatier is a leading psychiatric hospital located in France, renowned for its commitment to advancing mental health care through innovative research and clinical trials. With a focus on integrating clinical practice and scientific inquiry, the institution aims to enhance treatment protocols and therapeutic outcomes for individuals with psychiatric disorders. Hôpital Le Vinatier collaborates with multidisciplinary teams of healthcare professionals and researchers to conduct rigorous studies, ensuring the highest standards of ethical practice and patient safety. Its dedication to improving mental health services makes it a pivotal player in the field of psychiatric research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bron, , France
Patients applied
Trial Officials
Sébastien S CATOIRE, DR
Principal Investigator
Centre Hospitalier le Vinatier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported